Ksana Health partners with Beckley PsyTech!

At Ksana Health, we provide our continuous behavior measurement platform (CBHM), Effortless Assessment of Risk States (EARS), to clinical researchers. This platform has given them richer insight into the passive behavior of their study participants. Recently, we have been exploring how this platform can help psychedelic pharma better understand the behavioral effects of its medications. An important incremental value of EARS is its ability to measure behavior in real-time, between clinic visits and beyond study participant self-reporting.

We are gratified to announce our first partnership with a psychedelic pharma company, Beckley PsyTech! This partnership focuses on the collection and analysis of digital biomarkers. This focus will identify signs of response and relapse in Phase 2 clinical trials. It will also track and improve the patient experience Beckley PsyTech is developing alongside its medication.

This partnership strengthens Ksana Health’s track record in applying its CBHM capability to a broad array of clinical research contexts. Read more in this press release.

If you are a researcher, running studies with real-world behavioral endpoints, we would love to demonstrate our capability for you. Our demo request form is here.

 

Craig DeLarge

4 August 2022

Share on:

Recent Articles

Ksana Health Founder weighs in on Psychedelics & Technology

Palo Santo, a venture fund focused on psychedelic therapeutics and a Ksana Health investor, took a survey of the perspectives of a number of thought leaders in the psychedelics space in light...

Continue reading

Podcast Alert: Novo Nordisk’s Business Innovation Garage speaks to the value of Partnering with Innovative Startups

Recently Ksana Health was highlighted in an interview with Matt Dugan, Head of Business Innovation Garage at Global IT, Novo Nordisk. Kim Stensdal of The Danish IT Society conducted this interview on...

Continue reading

Ksana Health partners with Beckley PsyTech!

At Ksana Health, we provide our continuous behavior measurement platform (CBHM), Effortless Assessment of Risk States (EARS), to clinical researchers. This platform has given them richer insight into the passive behavior of...

Continue reading